Treatment selection for moderate to severe plaque psoriasis in special populations
AW Armstrong - UpToDate. Waltham, MA.: UpToDate, 2020 - uptodate.com
Topical therapy is the primary mode of treatment for plaque psoriasis in patients with limited
skin involvement but is often insufficient for patients with moderate to severe plaque …
skin involvement but is often insufficient for patients with moderate to severe plaque …
Protocol of Kasr Al-Ainy's Phototherapy Unit-Cairo University for the management of photo-responsive skin diseases-part 2: protocol of phototherapeutic management …
MA El-Mofty, WZ Mostafa, SM Esmat… - Journal of the …, 2023 - journals.lww.com
One of the most commonly used and effective lines of treatment in chronic skin diseases is
phototherapy. A protocol of the Kasr Al-Ainy Phototherapy Unit has been proposed for the …
phototherapy. A protocol of the Kasr Al-Ainy Phototherapy Unit has been proposed for the …
[HTML][HTML] Cyclosporine as monotherapy for psoriasis in the setting of chronic HCV infection: A forgotten therapeutical option
AMG Brunasso, P Michetti, L Fancelli… - Hepatitis Monthly, 2012 - ncbi.nlm.nih.gov
Background Treatment of psoriasis in the setting of chronic hepatitis C virus (HCV) infection
is difficult, because standard therapies like methotrexate are associated with increased …
is difficult, because standard therapies like methotrexate are associated with increased …
Use of cyclosporin in a patient with hepatitis C and pustular psoriasis
L Bomm, CC Zimmermann, R Souto… - Anais Brasileiros de …, 2011 - SciELO Brasil
Cyclosporine has been con train di ca ted in patients with chro nic infec tions such as infec
tion with hepa ti tis C becau se of its immu no sup pres si ve effect. Recent stu dies have …
tion with hepa ti tis C becau se of its immu no sup pres si ve effect. Recent stu dies have …
Is universal screening for hepatitis C infection prior to commencing antitumour necrosis factor‐α therapy necessary?
CT Reid, C De Gascun, W Hall, P Collins… - British Journal of …, 2013 - academic.oup.com
Background Screening for hepatitis C virus (HCV) prior to the commencement of antitumour
necrosis factor (anti‐TNF)‐α therapies for dermatological disease is recommended for all …
necrosis factor (anti‐TNF)‐α therapies for dermatological disease is recommended for all …
Treatment of psoriasis with cyclosporine in patients with hepatitis C infection: Risk or opportunity?
V Di Lernia, G Albertini - Journal of the American Academy of Dermatology, 2010 - jaad.org
To the Editor: We appreciated the article by Frankel et al 1 in the December 2009 issue of
the Journal regarding the treatment of psoriasis in patients with hepatitis C virus (HCV) …
the Journal regarding the treatment of psoriasis in patients with hepatitis C virus (HCV) …
Treatment of psoriasis vulgaris: guidelines of experts of the Polish Dermatological Society. Part II: moderate to severe psoriasis
J Szepietowski, Z Adamski, G Chodorowska… - Dermatology Review …, 2014 - termedia.pl
Łuszczyca jest przewlekłą chorobą zapalną skóry, która występuje u około 1–3% populacji
ogólnej. Etiologia tego schorzenia nadal nie została w pełni wyjaśniona, chociaż …
ogólnej. Etiologia tego schorzenia nadal nie została w pełni wyjaśniona, chociaż …
Serum levels of IL-12 and IL-23 in psoriatic patients with or without concomitant hepatitis C: a comparative study
Background A role for hepatitis C virus (HCV) infection in psoriasis has been proposed, but
the underlying pathogenic mechanisms are still undetermined. Interleukin (IL)-12 and IL-23 …
the underlying pathogenic mechanisms are still undetermined. Interleukin (IL)-12 and IL-23 …
Biologics: New drugs, new adverse reactions
JC Prinz - Der Hautarzt, 2010 - Springer
Biologics sind eine in der Dermatologie seit dem Jahr 2004 verfügbare
Medikamentengruppe zur Therapie der mittelschweren bis schweren chronischen Plaque …
Medikamentengruppe zur Therapie der mittelschweren bis schweren chronischen Plaque …
Etanercept for the treatment of psoriasis
M Ara, E Daudén - Expert Review of Dermatology, 2013 - Taylor & Francis
Etanercept is a systemic tumor necrosis factor-α inhibitor indicated for use in the treatment of
rheumatoid arthritis, polyarticular juvenile idiopathic arthritis, psoriatic arthritis, ankylosing …
rheumatoid arthritis, polyarticular juvenile idiopathic arthritis, psoriatic arthritis, ankylosing …